Novartis AG (NVS)
161.46
+9.40
(+6.18%)
USD |
NYSE |
Sep 01, 15:15
Novartis Cash from Operations (Annual) : 19.24B for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 19.24B |
| December 31, 2024 | 17.61B |
| December 31, 2023 | 14.46B |
| December 31, 2022 | 14.26B |
| December 31, 2021 | 15.07B |
| December 31, 2020 | 13.73B |
| December 31, 2019 | 13.62B |
| December 31, 2018 | 14.30B |
| December 31, 2017 | 12.65B |
| December 31, 2016 | 11.48B |
| December 31, 2015 | 11.90B |
| December 31, 2014 | 13.90B |
| December 31, 2013 | 13.22B |
| December 31, 2012 | 14.29B |
| December 31, 2011 | 14.16B |
| December 31, 2010 | 13.95B |
| December 31, 2009 | 12.14B |
| Date | Value |
|---|---|
| December 31, 2008 | 9.769B |
| December 31, 2007 | 9.21B |
| December 31, 2006 | 8.351B |
| December 31, 2005 | 7.962B |
| December 31, 2004 | 6.586B |
| December 31, 2003 | 6.603B |
| December 31, 2002 | 5.246B |
| December 31, 2001 | 4.348B |
| December 31, 2000 | 4.505B |
| December 31, 1999 | 4.583B |
| December 31, 1998 | 4.062B |
| December 31, 1997 | 3.226B |
| December 31, 1996 | 3.837B |
| December 31, 1995 | 4.850B |
| December 31, 1994 | 3.694B |
| December 31, 1993 | 3.430B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Roche Holding AG | 21.47B |
| AstraZeneca PLC | 14.90B |
| Johnson & Johnson | 24.53B |
| Eli Lilly & Co. | 16.81B |
| Merck & Co., Inc. | 16.47B |